Overcoming Acquired Epigenetic Resistance to BTK Inhibitors

Arthur L. Shaffer III and Louis M. Staudt, et al.

Lymphoid Malignancies Branch
National Cancer Institute
National Institutes of Health
9000 Rockville Pike
Bethesda, MD 20892

1. Access to Raw High-Throughput Datasets:

Readme_rawData_info.xlsx

Fig_2_scRNAseq_10X.tar

Fig_3_HBL1.TCF4.ChIPseq.hg19.wig.gz

Rest of raw datasets are availabe at NCBI database

2. Additional Supplementary Data:

SUPFigures IBR ms.docx

SUPMethods IBR.docx

SUPTable Oligos and Primers.xlsx

SUP_TABLE_X. Additional EXOME SEQ on IRpools from ABC lines.xlsx

SUP_TABLE_Y. HBL1_TMD8 barcode evolution raw counts.txt

SUP_TABLE_Z. HBL1 EBC data.xlsx

3. Official Supplementary Data (Same to the ones on journal's website):

SUPTable1_Epigenetic Ibrutinib Resistance in ABC DLBCL lines.xlsx

SUPTable2_Tracking the evolution of ibrutinib resistance phenotypes.xlsx

SUPTable3_Epigenetic retuning of oncogenic signaling in ibrutinib resistance.xlsx

SUPTable4_Altered dependencies in ibrutinib resistant ABC DLBCL.xlsx

SUPTable5_RAC2 as a mediator of epigenetic ibrutinib resistance.xlsx

SUPTable6_RAC2 protein interactions are a marker of epigenetic ibrutinib resistance .xlsx

SUPTable7_Targeting epigenetic resistance to BTK inhibitor treatment in ABC DLBCL.xlsx